Gilead files hep B therapy for FDA approval; Intellia launches gene editing subsidiary;

@FierceBiotech: Juno buys into sequencing; Moderna cozies up to Big Pharma; and more from . Article | Follow @FierceBiotech

@JohnCFierce: Sounds right. Deal fest in San Francisco while  takes an ugly 5% drop. Bon chance to you stock guys; off to a rough start at . | Follow @JohnCFierce

@DamianFierce: warm memories from last year's jp morgan when, after a full day of meetings, I found this on the back of my collar. More | Follow @DamianFierce

> Gilead Sciences ($GILD) filed its investigational tenofovir alafenamide for FDA approval in hepatitis B. News

> Moderna Therapeutics secured a $20 million grant from the Bill & Melinda Gates Foundation to advance its HIV candidate. More

> Intellia Therapeutics launched a new division focused on gene editing technology. Release

Medical Device News

@FierceMedDev: Medtronic to build Chinese facility for the manufacture of advanced diabetes devices. Article | Follow @FierceMedDev

@EmilyWFierce: Congressional reps urge the NIH to 'march in' on rising drug prices. FiercePharma story | Follow @EmilyWFierce

> JPM: Illumina's genomic ambitions fueled by new sequencing tools and technology. Story

> Boston Scientific launches disposable digital urinary tract endoscope. Article

> JPM: Medtronic aims for double-digit returns with more buybacks, faster dividends and debt paydown. More

Pharma News

@FiercePharma: BioAtla scores $45M investment for CAB development. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: ICYMI: U.K. investor Woodford calls again for breakup of 'complicated' GSK. Article | Follow @CarlyHFierce

> Celgene ends horse race for Hugin's successor, tapping Mark Alles as new CEO. Story

> Now focused on integrating Allergan generics, Teva eyes 'much larger' specialty buy in 2017. Article

Drug Delivery News

> Australia's Elastagen receives $9M to deploy its human protein formulation to aesthetics and tissue repair. News

> Back-of-the-eye delivery outfit Clearside files for $58 million IPO. Story

> One microcapsule could combine two drug ingredients when triggered at tumor site. More

> JPM: Halozyme to focus on its internal pancreatic cancer candidate in 2016. Report

> Xeris raises $41M to develop diabetes injection pen for glucagon administration. Article

Pharma Manufacturing News

> BD exiting sterile injectables biz, selling plant and portfolio to Fresenius Kabi. More

> Consent decree issued against recalcitrant compounder. Item

> Perrigo, already recalling Zyrtec copy, now recalling knockoff of Mucinex for children. Report

> FDA warning letter tells Cadila to resolve problems with warfarin production. Story

> European regulators sanction Chinese company for plant flaws. Article

Pharma Asia News

> BioAtla scores $45M investment for CAB development. More

> Japan's Takeda and enGene in GI therapy development pact. Item

> Glenmark's BEAT platform helps develop new cancer molecule. Article

> Amgen sues South Korea's Samsung Bioepis over Enbrel biosimilar. Report

> Singapore's NRF unveils 5-year, $13B research budget. Story

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.